Report Thumbnail
Product Code QY0914214488AFS
Published Date 2024/6/17
QY Research
English150 PagesGlobal

Global Neuromyelitis Optica Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY0914214488AFS◆The Jun 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/6/17
QY Research
English 150 PagesGlobal

Global Neuromyelitis Optica Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 47 million in 2023 and is forecast to a readjusted size of US$ 58 million by 2030 with a CAGR of 3.0% during the forecast period 2024-2030.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.
The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

Table of Contents

  • 1 Study Coverage

    • 1.1 Neuromyelitis Optica Drug Product Introduction
    • 1.2 Market by Type
      • 1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
      • 1.2.2 Glucocorticoids
      • 1.2.3 Immunotherapies
      • 1.2.4 Others
    • 1.3 Market by Application
      • 1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
      • 1.3.2 Acute Attack
      • 1.3.3 Remission Prophylactic Treatment
    • 1.4 Assumptions and Limitations
    • 1.5 Study Objectives
    • 1.6 Years Considered

  • 2 Executive Summary

    • 2.1 Global Neuromyelitis Optica Drug Market Size Estimates and Forecasts
    • 2.2 Neuromyelitis Optica Drug Market Size by Region: 2023 Versus 2030
      • 2.2.1 Global Neuromyelitis Optica Drug Revenue by Region: 2019-2024
      • 2.2.2 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2025-2030)
      • 2.2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2030)

  • 3 Global Neuromyelitis Optica Drug by Company

    • 3.1 Global Neuromyelitis Optica Drug Revenue by Company (2019-2024)
    • 3.2 Global Neuromyelitis Optica Drug Revenue Share by Company (2019-2024)
    • 3.3 Competitive Landscape
      • 3.3.1 Key Neuromyelitis Optica Drug Companies around the World: Ranking by Revenue
      • 3.3.2 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI) & (2019-2024)
      • 3.3.3 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.4 Global Neuromyelitis Optica Drug Companies Headquarters & Product Type
      • 3.4.1 Neuromyelitis Optica Drug Companies Headquarters
      • 3.4.2 Global Neuromyelitis Optica Drug Companies Product & Service
      • 3.4.3 Date of International Companies Enter into Neuromyelitis Optica Drug Market
    • 3.5 Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans

  • 4 Company Profiles

    • 4.1 Pfizer
      • 4.1.1 Pfizer Company Information
      • 4.1.2 Pfizer Description, Business Overview
      • 4.1.3 Pfizer Neuromyelitis Optica Drug Products Offered
      • 4.1.4 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.1.5 Pfizer Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.1.6 Pfizer Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.1.7 Pfizer Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.1.8 Pfizer Recent Developments
    • 4.2 Fresenius
      • 4.2.1 Fresenius Company Information
      • 4.2.2 Fresenius Description, Business Overview
      • 4.2.3 Fresenius Neuromyelitis Optica Drug Products Offered
      • 4.2.4 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.2.5 Fresenius Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.2.6 Fresenius Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.2.7 Fresenius Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.2.8 Fresenius Recent Developments
    • 4.3 Teva
      • 4.3.1 Teva Company Information
      • 4.3.2 Teva Description, Business Overview
      • 4.3.3 Teva Neuromyelitis Optica Drug Products Offered
      • 4.3.4 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.3.5 Teva Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.3.6 Teva Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.3.7 Teva Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.3.8 Teva Recent Developments
    • 4.4 Sandoz
      • 4.4.1 Sandoz Company Information
      • 4.4.2 Sandoz Description, Business Overview
      • 4.4.3 Sandoz Neuromyelitis Optica Drug Products Offered
      • 4.4.4 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.4.5 Sandoz Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.4.6 Sandoz Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.4.7 Sandoz Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.4.8 Sandoz Recent Developments
    • 4.5 Intas
      • 4.5.1 Intas Company Information
      • 4.5.2 Intas Description, Business Overview
      • 4.5.3 Intas Neuromyelitis Optica Drug Products Offered
      • 4.5.4 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.5.5 Intas Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.5.6 Intas Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.5.7 Intas Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.5.8 Intas Recent Developments
    • 4.6 Gyjtrs
      • 4.6.1 Gyjtrs Company Information
      • 4.6.2 Gyjtrs Description, Business Overview
      • 4.6.3 Gyjtrs Neuromyelitis Optica Drug Products Offered
      • 4.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.6.5 Gyjtrs Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.6.6 Gyjtrs Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.6.7 Gyjtrs Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.6.8 Gyjtrs Recent Development
    • 4.7 NANG KUANG
      • 4.7.1 NANG KUANG Company Information
      • 4.7.2 NANG KUANG Description, Business Overview
      • 4.7.3 NANG KUANG Neuromyelitis Optica Drug Products Offered
      • 4.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.7.5 NANG KUANG Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.7.6 NANG KUANG Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.7.7 NANG KUANG Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.7.8 NANG KUANG Recent Development
    • 4.8 Tianjin Kingyork
      • 4.8.1 Tianjin Kingyork Company Information
      • 4.8.2 Tianjin Kingyork Description, Business Overview
      • 4.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products Offered
      • 4.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.8.5 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.8.6 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.8.7 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.8.8 Tianjin Kingyork Recent Development
    • 4.9 Baxter
      • 4.9.1 Baxter Company Information
      • 4.9.2 Baxter Description, Business Overview
      • 4.9.3 Baxter Neuromyelitis Optica Drug Products Offered
      • 4.9.4 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.9.5 Baxter Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.9.6 Baxter Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.9.7 Baxter Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.9.8 Baxter Recent Development
    • 4.10 CSL
      • 4.10.1 CSL Company Information
      • 4.10.2 CSL Description, Business Overview
      • 4.10.3 CSL Neuromyelitis Optica Drug Products Offered
      • 4.10.4 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.10.5 CSL Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.10.6 CSL Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.10.7 CSL Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.10.8 CSL Recent Development
    • 4.11 Grifols
      • 4.11.1 Grifols Company Information
      • 4.11.2 Grifols Description, Business Overview
      • 4.11.3 Grifols Neuromyelitis Optica Drug Products Offered
      • 4.11.4 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.11.5 Grifols Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.11.6 Grifols Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.11.7 Grifols Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.11.8 Grifols Recent Development
    • 4.12 Octapharma
      • 4.12.1 Octapharma Company Information
      • 4.12.2 Octapharma Description, Business Overview
      • 4.12.3 Octapharma Neuromyelitis Optica Drug Products Offered
      • 4.12.4 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.12.5 Octapharma Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.12.6 Octapharma Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.12.7 Octapharma Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.12.8 Octapharma Recent Development
    • 4.13 CBOP
      • 4.13.1 CBOP Company Information
      • 4.13.2 CBOP Description, Business Overview
      • 4.13.3 CBOP Neuromyelitis Optica Drug Products Offered
      • 4.13.4 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)
      • 4.13.5 CBOP Neuromyelitis Optica Drug Revenue by Product in 2023
      • 4.13.6 CBOP Neuromyelitis Optica Drug Revenue by Application in 2023
      • 4.13.7 CBOP Neuromyelitis Optica Drug Revenue by Geographic Area in 2023
      • 4.13.8 CBOP Recent Development

  • 5 Breakdown Data by Type

    • 5.1 Global Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 5.2 Global Neuromyelitis Optica Drug Revenue Forecast by Type (2025-2030)
    • 5.3 Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2030)

  • 6 Breakdown Data by Application

    • 6.1 Global Neuromyelitis Optica Drug Revenue by Application (2019-2024)
    • 6.2 Global Neuromyelitis Optica Drug Revenue Forecast by Application (2025-2030)
    • 6.3 Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2030)

  • 7 North America

    • 7.1 North America Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030
    • 7.2 North America Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)
    • 7.3 North America Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 7.4 North America Neuromyelitis Optica Drug Revenue by Application (2019-2024)

  • 8 Asia-Pacific

    • 8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030
    • 8.2 Asia-Pacific Neuromyelitis Optica Drug Market Facts & Figures by Region (2019-2030)
    • 8.3 Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 8.4 Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2019-2024)

  • 9 Europe

    • 9.1 Europe Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030
    • 9.2 Europe Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)
    • 9.3 Europe Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 9.4 Europe Neuromyelitis Optica Drug Revenue by Application (2019-2024)

  • 10 Latin America

    • 10.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030
    • 10.2 Latin America Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)
    • 10.3 Latin America Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 10.4 Latin America Neuromyelitis Optica Drug Revenue by Application (2019-2024)

  • 11 Middle East and Africa

    • 11.1 Middle East and Africa Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030
    • 11.2 Middle East and Africa Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)
    • 11.3 Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2019-2024)
    • 11.4 Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2019-2024)

  • 12 Supply Chain and Sales Channel Analysis

    • 12.1 Neuromyelitis Optica Drug Supply Chain Analysis
    • 12.2 Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers
    • 12.3 Neuromyelitis Optica Drug Clients Analysis
    • 12.4 Neuromyelitis Optica Drug Sales Channel and Sales Model Analysis
      • 12.4.1 Neuromyelitis Optica Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales
      • 12.4.2 Neuromyelitis Optica Drug Distribution Channel Analysis: Online Sales VS Offline Sales
      • 12.4.3 Neuromyelitis Optica Drug Distributors

  • 13 Market Dynamics

    • 13.1 Neuromyelitis Optica Drug Industry Trends
    • 13.2 Neuromyelitis Optica Drug Market Drivers
    • 13.3 Neuromyelitis Optica Drug Market Challenges
    • 13.4 Neuromyelitis Optica Drug Market Restraints

  • 14 Research Findings and Conclusion

  • 15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details
    • 15.3 Disclaimer
USD 5,900 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.